Showing 5531-5540 of 9771 results for "".
- Acne Pipeline Watch: Dermata Therapeutics Completes Enrollment in Phase 2b Trial of Once-Weekly Topical DMT310 for Acnehttps://practicaldermatology.com/news/acne-pipeline-watch-dermata-therapeutics-completes-enrollment-in-phase-2b-trial-of-once-weekly-topical-dmt310-for-acne/2460282/Dermata Therapeutics, LLC completed enrollment of patients in its Phase 2b clinical trial evaluating the safety, tolerability and efficacy of DMT310 in moderate to severe acne patients. The Phase 2b trial enrolled 182 patients randomly in two group
- Sun Pharma's New Ad Campaign Raises Awareness of Acne and its Impacthttps://practicaldermatology.com/news/sun-pharmas-new-ad-campaign-raises-awareness-of-acne-and-its-impact-1/2460280/Sun Dermatology, a division of Sun Pharmaceutical Industries, Inc., USA, launched Take on Acne – a new advertising campaign designed to raise awareness of the profound impact of acne on everyday life, particularly among teenagers and young adults (roughly 12-25 years of age). Acne af
- Half of Lupus Rashes Harbor High Levels of Staph Bacteriahttps://practicaldermatology.com/news/half-of-lupus-rashes-harbor-high-levels-of-staph-bacteria/2460279/Fifty percent of skin rashes in patients with lupus contain an abnormally high presence of Staphylococcus aureus bacteria, according to a study in the Journal of Investigative Dermatology. In addition, researchers found tha
- Revance: FDA Accepts BLA for DaxibotulinumtoxinA, Sets November PDUFA Datehttps://practicaldermatology.com/news/revance-fda-accepts-bla-for-daxibotulinumtoxina-sets-november-pdufa-date/2460278/FDA has accepted the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines, Revance reports. The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.
- SkinMedica Launches DiamondGlowhttps://practicaldermatology.com/news/skinmedica-launches-diamondglow/2460270/Allergan’s Skinmedica is rolling out DiamondGlow, a non-invasive dermabrasion technology that exfoliates, extracts, and treats the face, eye area, lips and body. Allergan acquired Envy Medical, Inc and its Silkpeel Dermalinfusion in 2
- Mattel Releases New Barbie Dolls with Vitiligo, Alopeciahttps://practicaldermatology.com/news/mattel-releases-new-barbie-dolls-with-vitiligo-alopecia-1/2460268/In an effort to be more inclusive, Mattel, the maker of Barbie dolls, has released new dolls in its Fashionista line including a Barbie with alopecia and one with vitiligo. “For 2020, Barbie is continuing the journey to represent global diversity and inclusivity in the f
- Alma Rolls Out Opus Plasmahttps://practicaldermatology.com/news/alma-rolls-out-opus-plasma/2460264/Alma, Inc. is launching Opus in North America. Opus is a new platform featuring the company's proprietary high-frequency unipolar radio-frequency technology, Opus Plasma. Opus Plasma is the first fractional plasma technology to enter the f
- Crown Aesthetics Introduces Progen PRP Advantagehttps://practicaldermatology.com/news/crown-aesthetics-introduces-progen-prp-advantage/2460263/Crown Aesthetics, a division of Crown Laboratories, Inc., launched ProGen PRP Advantage, an easy-to-use, single-spin system that features 15ml and 30ml tubes, yielding 7-15ml of 2x concentration PRP. With the launch of
- FDA Follow-Up Study: Sunscreen Active Ingredients Are Absorbed by Bloodstreamhttps://practicaldermatology.com/news/fda-follow-up-study-sunscreen-active-ingredients-are-absorbed-by-bloodstream/2460258/Six active ingredients administered in four different sunscreen formulations are systemically absorbed, according to a new report. The study was sponsored by U.S. Food and Drug Administration (FDA) and is a follow-up to a May 2019 study that generated a lot of headlines. The new report
- Revance Acquires Exclusive US Distribution Rights to Teoxane SA Fillershttps://practicaldermatology.com/news/revance-acquires-exclusive-us-distribution-rights-to-teoxane-sa-fillers-1/2460250/Revance Therapeutics, Inc. is the exclusive commercialization partner of Teoxane SA in the US. With a new distribution agreement just announced, Revance gains immediate and exclusive rights to commercialize Teoxane’s Resilient Hyaluronic Acid® (RHA®) line of fillers in the